Changes in cytokeratins following treatment of hamster cheek pouch epithelia with hyperplastic or neoplastic agents.
The effects of four different hyperplastic agents and of the carcinogen DMBA on cytokeratin expression in hamster cheek pouch epithelia were compared. Reversible hyperplasia was produced by the application of either oil of turpentine, vitamin A or TPA. No hyperplastic changes were produced by application of EPP. Apart from the transient appearance of a 45 kDa cytokeratin in one group treated with vitamin A, the immunohistochemical staining patterns and immunoblot profiles of cytokeratins from cheek pouches treated with each of the hyperplastic agents were identical to controls. Following application of DMBA, the cytokeratins stained with increased intensity in the spinous and granular cell layers. This was associated with increased amounts of 42-56 kDa cytokeratins and decreased production of 62-75 kDa cytokeratins. Monoclonal antibody AE1 detected a 45 kDa cytokeratin in extracts of DMBA-treated epithelia that was not detected in untreated epithelial extracts. Monoclonal antibody AE3 detected an additional 54 kDa cytokeratin band in extracts of DMBA-treated epithelia. These cytokeratin changes were present in preneoplastic epithelia and maintained in neoplastic epithelia.
Shearer
B H
BH
Department of Oral Biology and Oral Pathology, University of Otago, Dunedin, New Zealand.
Jenkinson
H F
HF
McMillan
M D
MD
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000494:pharmacology*; D000480:Alkynes / Q000494:pharmacology*; D000818:Animals; D006224:Cricetinae; D004224:Diterpenes; D004848:Epithelium / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D006965:Hyperplasia; D015151:Immunoblotting; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis / Q000187:drug effects* / Q000235:genetics; D008297:Male; D008970:Molecular Weight; D009061:Mouth Mucosa / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D009062:Mouth Neoplasms / Q000737:chemistry / Q000473:pathology; D011230:Precancerous Conditions / Q000737:chemistry / Q000473:pathology; D000084562:Retinyl Esters; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D014425:Turpentine / Q000494:pharmacology*; D014801:Vitamin A / Q000031:analogs & derivatives* / Q000494:pharmacology
D000480:Alkynes; D004224:Diterpenes; D000084562:Retinyl Esters; D014801:Vitamin A; C014794:retinol palmitate; C015202:ethylphenylpropiolate; D015127:9,10-Dimethyl-1,2-benzanthracene; D007633:Keratins; D013755:Tetradecanoylphorbol Acetate; D014425:Turpentine